4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
9.28
-0.38 (-3.93%)
Mar 2, 2026, 2:06 PM EST - Market open
4D Molecular Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for 4D Molecular Therapeutics stock have an average target of 34.13, with a low estimate of 26 and a high estimate of 40. The average target predicts an increase of 267.78% from the current stock price of 9.28.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 28, 2026.
Analyst Ratings
The average analyst rating for 4D Molecular Therapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Initiates $33 | Buy | Initiates | $33 | +255.60% | Jan 28, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $26 | Strong Buy | Maintains | $26 | +180.17% | Dec 18, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $26 → $32 | Buy | Maintains | $26 → $32 | +244.83% | Nov 11, 2025 |
| Barclays | Barclays | Buy Maintains $38 → $33 | Buy | Maintains | $38 → $33 | +255.60% | Nov 11, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 → $26 | Strong Buy | Maintains | $25 → $26 | +180.17% | Nov 11, 2025 |
Financial Forecast
Revenue This Year
7.89M
from 37.00K
Increased by 21,227.03%
Revenue Next Year
20.66M
from 7.89M
Increased by 161.87%
EPS This Year
-3.75
from -2.98
EPS Next Year
-3.55
from -3.75
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 19.0M | 53.9M | ||||
| Avg | 7.9M | 20.7M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 51,264.9% | 582.6% | ||||
| Avg | 21,227.0% | 161.9% | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -3.47 | -2.73 | ||||
| Avg | -3.75 | -3.55 | ||||
| Low | -3.82 | -4.21 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.